17930234. COMPOSITIONS, METHODS, MODELS AND USES FOR SIMIAN VARICELLA VIRUS (SVV) CHIMERIC CONSTRUCTS IN HUMAN HEALTH CONDITIONS simplified abstract (THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE)

COMPOSITIONS, METHODS, MODELS AND USES FOR SIMIAN VARICELLA VIRUS (SVV) CHIMERIC CONSTRUCTS IN HUMAN HEALTH CONDITIONS

Organization Name

THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

Inventor(s)

Ravi Mahalingam of Aurora CO (US)

Vicki L. Traina-dorge of Covington LA (US)

Hua Zhu of Plainsboro NJ (US)

COMPOSITIONS, METHODS, MODELS AND USES FOR SIMIAN VARICELLA VIRUS (SVV) CHIMERIC CONSTRUCTS IN HUMAN HEALTH CONDITIONS - A simplified explanation of the abstract

This abstract first appeared for US patent application 17930234 titled 'COMPOSITIONS, METHODS, MODELS AND USES FOR SIMIAN VARICELLA VIRUS (SVV) CHIMERIC CONSTRUCTS IN HUMAN HEALTH CONDITIONS

Simplified Explanation

Embodiments of the instantly claimed inventions include chimeric viral constructs, non-human primate models, in vivo screening systems for antiviral agents, gene therapy delivery systems, and methods of making and using the same.

• Chimeric viral constructs: These constructs consist of a non-human primate infecting virus nucleic acid sequence and an exclusively human pathogenic virus nucleic acid sequence for creating a non-human primate model.
• In vivo screening systems for antiviral agents: These systems are designed to test the effectiveness of antiviral agents.
• Gene therapy delivery systems: These systems can deliver a vector containing or associated with an agent to a human subject for treating conditions of the skin and neuronal ganglia.

Potential Applications

The technology described in this patent application could be applied in the development of new antiviral treatments, gene therapy for skin and neuronal conditions, and the creation of non-human primate models for research purposes.

Problems Solved

This technology addresses the need for more effective antiviral agents, improved gene therapy delivery systems, and better research models for studying human pathogenic viruses.

Benefits

The benefits of this technology include potential advancements in antiviral treatments, gene therapy for various conditions, and a better understanding of viral infections through non-human primate models.

Potential Commercial Applications

Potential commercial applications of this technology could include the development of new antiviral drugs, gene therapy products for skin and neuronal conditions, and services related to non-human primate research models.

Possible Prior Art

One possible prior art in this field could be existing gene therapy delivery systems and antiviral screening methods that have been previously patented or published in scientific literature.

How does this technology compare to existing antiviral treatments and gene therapy delivery systems in terms of efficacy and safety?

The article does not provide a direct comparison between this technology and existing treatments or delivery systems. Further research and clinical trials would be needed to determine the effectiveness and safety of these new innovations.

What are the potential ethical considerations surrounding the use of non-human primate models in research for human pathogenic viruses?

The article does not address the ethical implications of using non-human primate models in research. Ethical discussions and guidelines may need to be considered before implementing this technology in research settings.

Original Abstract Submitted

Embodiments of the instantly claimed inventions include, but are not limited to, chimeric viral constructs, non-human primate models, in vivo screening systems for antiviral agents, gene therapy delivery systems, and methods of making and using the same. In some embodiments, chimeric viral constructs include a non-human primate infecting virus nucleic acid sequence and a exclusively human pathogenic virus nucleic acid sequence for use in creating a non-human primate model and uses thereof. In other embodiments, systems for testing antiviral agents are disclosed. In other embodiments, gene therapy delivery systems disclosed herein can be used to deliver a vector containing or associated with an agent to a human subject for treating conditions of the skin and neuronal ganglia in the subject.